Old Web
English
Sign In
Acemap
>
Paper
>
OA01.06 Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC
OA01.06 Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC
2021
G. Lai
J. Álvarez
J.-C. Yeo
N.L. Sim
Aaron C. Tan
S. Zhou
L. Suteja
T. W. Lim
Neha Rohatgi
J Yeong
Angela Takano
Kiat Hon Lim
Apoorva Gogna
Chow Wei Too
K.D. Zhuang
Amit Jain
Wan Ling. Tan
Ravindran Kanesvaran
Quan Sing Ng
Mei-Kim Ang
T. Rajasekaran
L. Wang
Chee Keong Toh
Wan-Teck Lim
Wai Leong Tam
F. Ginhoux
Sze Huey Tan
Anders Jacobsen Skanderup
D. Tan
E.-H. Tan
Keywords:
Oncology
Internal medicine
Ipilimumab
Nivolumab
Medicine
Mutant
Phases of clinical research
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI
[]